(Circulation. 2000;101:899.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Alteration in Left Ventricular Diastolic Filling and Accumulation of Myocardial Collagen at Insulin-Resistant Prediabetic Stage of a Type II Diabetic Rat Model
From the Second Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan.
Correspondence to Katsufumi Mizushige, MD, Second Department of Internal Medicine, Kagawa Medical University, 1750-1, Miki, Kita, Kagawa 761-0793, Japan. E-mail katsumz{at}kms.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Considerable controversy exists regarding impairment of cardiac function in diabetes mellitus (DM). We investigated the serial changes in left ventricular (LV) histopathology and LV filling dynamics in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which have been established as an animal model of type II DM.
Methods and Results—In 54 OLETF and 54 non-DM rats, body weight, blood pressure, heart rate, and transmitral pulsed Doppler examinations were performed from 5 to 47 weeks of age. An oral glucose tolerance test was performed at 10, 20, and 30 weeks of age. The hearts were excised for histopathology, including immunohistochemistry and histomorphometry of collagen, and measurement of hydroxyproline at baseline and each stage of developing DM. In the prediabetic stage (15 weeks of age), in which fast blood glucose remained normal, OLETF rats manifested mild obesity, postprandial hyperglycemia, and hyperinsulinemia, and early diastolic transmitral inflow exhibited prolonged deceleration time (OLETF, 59±10 ms versus non-DM, 49±8 ms, P<0.01) and low peak velocity (OLETF, 73±11 cm/s versus non-DM, 88±11 cm/s, P<0.01). Histopathology revealed extracellular fibrosis and abundant transforming growth factor-ß1 receptor II in LV myocytes of OLETF rats. At 15 weeks of age, the ratio of collagen area/visual field of LV wall in OLETF rats (8.3±1.3%) was larger than that in non-DM rats (4.9±1.8%, P<0.0001), and the collagen content/dry tissue weight ratio of heart was significantly higher in OLETF (2.0±0.5 mg/g) than non-DM (1.3±0.2 mg/g, P<0.01) rats.
Conclusions—A metabolic abnormality present in the prestage of type II DM may produce LV fibrosis and alteration in cardiac function.
Key Words: diabetes mellitus • diastole • collagen • echocardiography
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The principal pathophysiological feature of diabetes mellitus (DM) is the morphological and functional alteration of microvessels, called diabetic microangiopathy. Conversely, the presence of myocardial dysfunction independent of coronary artery disease in DM, "diabetic cardiomyopathy," has been well documented.1 Such focal changes in microvessels are not sufficient to account for the diffuse myocardial degeneration with interstitial fibrosis in diabetic cardiomyopathy. The causal link between microangiopathy and the pathogenesis of diabetic cardiomyopathy remains to be elucidated.1
Usually, an abnormality of relaxation is the earliest manifestation of cardiac dysfunction, and diastolic impairment presents before systolic impairment.2 3 4 Recently, Doppler echocardiography has become well accepted as a reliable, reproducible, and noninvasive method for diagnosis and longitudinal follow-up of subjects with diastolic dysfunction.5 Doppler flow velocity pattern represents the overall diastolic filling characteristics of the heart and can be useful in the diagnosis of diastolic dysfunction.6
However, definition of the natural history of DM heart function with Doppler echocardiography is limited, because most patients do not have a prediabetic study, and most patients receive treatments in the full-blown stage of DM or after having DM complications. Therefore, the use of an appropriate animal model may allow a better understanding of the processes that lead to diabetic cardiac dysfunction. Up to now, longitudinal follow-up animal studies looking at the progression of DM are rare. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat was recently established as an animal model of congenital DM by selective mating.7 The strain manifests stable clinical and pathological features that resemble human type II DM. Briefly, the characteristics of this strain are (1) late onset of hyperglycemia, (2) a mild and chronic course of DM, (3) mild obesity, (4) inheritance by males, and (5) renal and cardiac complications.
Using this model, we aimed to investigate the serial changes in left ventricular filling dynamics and histopathology and metabolic disorders, such as hyperglycemia, myocardial collagen accumulation, hyperinsulinemia, and insulin resistance during the process of DM formation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
Fifty-four male OLETFs were used as the experimental subjects, which were established by Kawano et al7 as spontaneously long-term hyperglycemic rats with type II DM. Fifty-four male Long-Evans Tokushima Otsuka (LETO) rats, which were developed from the same colony by selective mating but did not develop DM, were used as control animals. The starting age was 5 weeks. All of the OLETF and LETO rats were maintained at the Kagawa Medical University animal experiment center and were kept at the specific pathogen–free facility under controlled temperature (23±2°C) and humidity (55±5%) with a 12-hour artificial light and dark cycle. Animals were given free access to standard laboratory rat chow (MF, Oriental Yeast Co) and tap water. All procedures were in accordance with institutional guidelines for animal research.
Experimental Protocol
The numbers of rats in each group of OLETF or LETO rats are
summarized in Table 1
.
Systolic blood pressure was measured by the tail-cuff method
(sphygmomanometer PS-100 Rick, Riken Kaihatsu). Blood glucose after 7
hours of fasting was measured in tail capillary blood with a glucose
test meter (Glutest EII, Kyoto First Scientific Co) in the afternoon.
On the oral glucose tolerance test (OGTT) (glucose/body weight=2 g/kg),
blood glucose and insulin concentration (ELISA method) were measured at
baseline and 2 hours after loading. Rats were killed for
histopathology, immunohistochemistry, histomorphometry of
ventricular collagen, measurements of heart weight and
hydroxyproline, and blood sampling during the process of development of
DM.
|
Echocardiography
Each rat was anesthetized with 60 mg/kg sodium
pentobarbital, and the left side of the chest was shaved to gain a
clear image before pulsed Doppler
echocardiography was performed. All rats were
studied in the left lateral decubitus position for serial
echocardiographic examinations.
Echocardiographic equipment (Aloka SSD-2200, Aloka
Corp) with a 7.5-MHz transducer was used for Doppler
echocardiography. The transmitral flow velocity
profile was determined by positioning a sample volume at the tip of the
mitral valve on the para-apical long-axis view. The Doppler beam
was set with <30° of the incident angle to flow direction identified
on color Doppler image. The angle correction was performed by a
semiautomated system installed in the machine.
The peak velocity and deceleration time of the early diastolic filling wave were measured. The deceleration time was obtained by extrapolating the initial slope of early diastolic filling wave deceleration to the baseline. Transmitral inflow pattern was recorded on a strip chart at 100-mm/s sweep speed with simultaneous 3-lead ECG for offline analysis. All measurements represent the mean of 5 consecutive cardiac cycles, and heart rate was calculated on the basis of the strip chart of Doppler echocardiography.
Euthanasia and Histopathological Methods
Rats were anesthetized with 50 mg/kg sodium
pentobarbital. The hearts were excised, weighed, and separated into 2
halves along the anterior longitudinal middle line. Half of the heart
was fixed with formalin solution, and the specimens were embedded in
paraffin and cut into sections 4 µm thick for Azan-Mallory
staining and immunostaining of transforming growth
factor (TGF)-ß1 receptor II
(streptavidin/biotin immunoperoxidase method,8 9 10 11
VECTASTAIN Elite ABC kit, Vector Laboratories, Inc). Tissues
expressing TGF-ß1 receptor II appeared
brown.
The other half of the heart was frozen in liquid nitrogen and stored at -80°C for measurement of hydroxyproline content. Trunk blood was sampled for measurement of plasma total cholesterol (cholesterol oxydase-peroxydase method) and triglyceride (glycerokinase-glycerol-3-phosphooxydase method).
Histomorphometry in Ventricular
Interstitial Collagen Percentage
The specimens from OLETF and LETO rats at each age were
simultaneously stained by Azan-Mallory staining in the same
bath for an accurate histopathological comparison except for technical
differences between the 2 groups. Collagen deposition in
myocardium of the left and right ventricular
walls of each visual field was quantitatively measured on the sections
stained. Each field was entered into a computer as an image with 256
gray levels on which the collagen that stained blue appeared black. We
measured the collagen area at 3 sites on each slide using a threshold
function of NIH software. A correct surface detection of collagen area
was visually confirmed on the gray image by comparing the original
color image before measurement. The area darker than threshold value
was measured, and the percent collagen area per visual field area was
automatically computed. The mean value of the 3 measurements was used
for analysis.
Myocardial Hydroxyproline and Collagen Content
Specimens were dried and hydrolyzed in 6N HCl at 110°C for 24
hours. The hydrolyzed material was dried and reconstituted in 3 mL
H2O. Hydrolysate was mixed with ethanol and
chloramine T solution and oxidized for 20 minutes at room temperature.
The oxidized product was reacted with
p-dimethylaminobenzaldehyde in ethanol and
H2SO4 solution at 60°C
for 15 minutes, and the resulting chromophore was quantified
spectrophotometrically at 572 nm against a hydroxyproline standard
curve. Because hydroxyproline is incorporated only into collagen and
assuming that collagen contains 14% hydroxyproline, the total collagen
content per dry weight can be calculated.12 13 14
Statistical Analysis
All values are represented as mean±SD. Statistical
differences were determined by ANOVA with Statview software (Power PC
version, Abacus Concepts Inc). Comparison of values was done between
the age-matched OLETF and LETO rats by the Mann-Whitney U
test. Statistical comparison of serial changes was performed by 1-way
ANOVA. Paired Student’s t test was used to compare serial
changes in serum glucose and insulin concentration during OGTT. A
probability value of <0.05 was considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Blood Pressure, Heart Rate, and Body and Heart Weight
There was no constant tendency in the systolic blood pressure or heart rate despite significant but small differences at all ages. After 9 weeks of age, body weight showed a significant difference. At 17, 26, and 47 weeks, the heart weight of OLETF rats was significantly larger than that of LETO rats. No significant difference in ratio of heart weight to body weight between OLETF and LETO rats was observed (Fig-ure 1).
Glucose and Lipid Metabolism
From 9 to 47 weeks of age, the fast blood glucose in OLETF rats
was always higher than that in LETO rats. At only 37 weeks, the fast
blood glucose of OLETF rats was >120 mg/dL (Figure 2).
|
On OGTT, baseline blood glucose of OLETF and LETO rats was within the
normal range, although baseline blood glucose of OLETF was
significantly higher than that of LETO rats. At 10 and 20 weeks of age,
the 2-hour blood glucose of OLETF rats was significantly higher than
that of LETO rats and did not return to baseline level. At 30 weeks,
OLETF rats could be diagnosed as impaired glucose tolerance. Plasma
insulin concentrations of OLETF rats were markedly higher than those of
LETO rats (Table 2).
|
At 31 and 47 weeks, the plasma total cholesterol and
triglyceride levels of OLETF rats were higher than those of
LETO rats (Figure 2
).
Doppler Echocardiography
Because it was impossible to separate the early
diastolic filling wave and late filling wave of transmitral
flow, we have to exclude the data of heart rate >390 bpm. Heart rate
and blood pressure values were not significantly different between
OLETF and LETO rats used for analysis of transmitral
inflow.
The deceleration time was prolonged and peak velocity was decreased in
OLETF rats compared with those in LETO rats from 11 to 27 weeks of age.
At 15 weeks, the deceleration times of OLETF versus LETO rats were
59±10 versus 49±8 ms (P<0.01), and the peak velocities of
OLETF versus LETO rats were 73±11 versus 88±11 cm/s
(P<0.01), respectively (Figures 3 and 4).
|
|
Myocardial Collagen Content
The collagen content/dry weight ratio in OLETF rats
(2.0±0.5 mg/g) was significantly larger than that in LETO rats
(1.3±0.2 mg/g, P<0.01) at 15 weeks of age, whereas no
significant difference was observed at 5, 31, and 47 weeks (Figure 5).
|
Histopathological Findings
At 5 and 7 weeks of age, no significant histopathological
differences between OLETF and LETO rats were observed. Figure 6 demonstrates the histopathological
sections by the Azan-Mallory staining and threshold images at 5 and 15
weeks of age. Interstitial fibrosis was marked after 15
weeks of age, and fibroblasts were more abundant at the ages of 31 and
47 weeks in the right and left ventricular walls of OLETF
rats. Collagen accumulation and no atherosclerotic changes were
observed.
|
The left ventricular collagen area per visual field (%)
gradually increased in OLETF and did not change significantly in LETO
rats throughout the protocol. At 5 weeks, the values were not
significantly different between OLETF (2.9±0.8) and LETO (4.3±1.4)
rats. At 15 weeks, the value of OLETF (8.3±1.3) was larger than that
of LETO (4.9±1.8, P<0.0001) rats (Figure 7). Right ventricular
collagen area per visual field (%) showed a tendency similar to that
in the left ventricle (5 weeks: OLETF, 4.8±1.2 versus LETO, 7.1±1.8,
P<0.001; 15 weeks: OLETF, 14.8±1.8 versus LETO, 7.7±2.3,
P=0.0001).
|
P<0.001 vs previous weeks; 
P<0.05
vs previous weeks.
The immunohistochemical stain of the left ventricle showed much more
TGF-ß1 receptor II expression in the myocytes
and endothelium of small arteries of OLETF rats than
did that in LETO rats at 15 weeks of age (Figure 8).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In patients with DM, Doppler echocardiographic studies have demonstrated that not only diabetes but also a minor degree of hyperglycemia will influence cardiac function.15 16 In these studies, the authors mentioned the possibility that other metabolic abnormalities associated with hyperglycemia might play a role in cardiac dysfunction. To the best of our knowledge, this is the first study that provides serial data on left ventricular diastolic function from the prediabetic stage in an animal model of developing DM along with data on glucose and lipid metabolism, ventricular collagen content, and cardiac histopathology.
Stages of DM in OLETF Rats
The fast blood glucose of OLETF rats was in the normal range and
was slightly but significantly higher than that in LETO rats after 9
weeks of age. On the basis of OGTT data, from 10 to 20 weeks of age,
the OLETF rats showed minor abnormalities in 2-hour serum glucose
(postprandial hyperglycemia) and relatively higher plasma insulin
levels both at baseline and 2 hours after loading compared with
age-matched LETO rats. Two-hour serum glucose of OLETF rats at 30 weeks
of age was >200 mg/dL. This demonstrates that the OLETF strain of rats
was in the stage of impaired glucose tolerance with hyperglycemia (by
World Health Organization diagnostic criteria) at 30 weeks
of age. After 9 weeks of age, OLETF rats showed mild obesity, which was
sustained up to 47 weeks of age. Both the plasma
cholesterol and triglyceride levels of OLETF
rats were significantly higher than those of LETO rats at 31 and 47
weeks of age, which suggested that from 30 to 47 weeks of age,
metabolic disorders were evident in OLETF rats. According
to previous reports7 17 18 and the present data, our
subjects were in the stage of prediabetes and insulin resistance at 10
to 20 weeks, impaired glucose tolerance at 30 weeks, and type II DM at
37 weeks.
Remodeling of Left Ventricle
Our results of a decrease in the ratio of collagen content/dry
weight of left ventricle from 5 to 15 weeks seemed to contradict
previous studies in myocardial fibrosis, which showed the ratio to
increase along with disease progression.19 We speculate
that from 5 to 15 weeks of age, the rats are undergoing developmental
transition. During this stage, both extracellular matrix (including
collagen) and cardiac myocyte content are increased, so it is
reasonable that the ratio decreased from 5 to 15 weeks of age. At 31
and 47 weeks, the ratio increased in both groups compared with that at
15 weeks, and there is no significant difference between the 2 groups.
Slightly augmented collagen deposition in the myocardial interstitium
and perivascular area during the maturational period of life was
reported previously in rat heart.20 Cardiac fibrosis and
collagen deposition may be related to premature aging and the processes
involved in cardiac extracellular remodeling in OLETF rats. Cardiac
fibrosis might play a role in progressive deterioration of cardiac
hemodynamics in aging and an explanation for the
diastolic dysfunction.
Transmitral Inflow Change
Usually, an abnormality of relaxation is the earliest
manifestation of a disease process. A primary abnormality of relaxation
produces specific changes in the mitral flow velocity curve, consisting
of a low velocity of early filling wave, a high velocity of late
filling wave, and a prolonged deceleration time of early filling
wave.5 6 In the present study, the deceleration time
of OLETF rats was prolonged, and peak velocity of early filling wave
was decreased from 11 to 27 weeks of age, which represents an
early manifestation of abnormality of left ventricular
diastolic function. During this stage, OLETF rats showed
postprandial hyperglycemia and hyperinsulinemia,
although the average fasting serum glucose was normal. This impairment
was evident at a preclinical stage of DM (prediabetes or impaired
glucose tolerance) and was accompanied by serological or pathological
findings. It was likely that alteration in the diastolic
function in the prediabetic stage was related to the remodeling of
myocardial tissue structure.21 22 23
The normal mitral flow velocity curve varies with age, loading conditions, and heart rate.5 In our study, therefore, we age-matched our control rats, measured the blood pressure immediately after finishing Doppler echocardiography, and subclassified the OLETF rats and LETO rats according to their heart rate.
The pattern of left ventricular filling that we have documented in OLETF rats with DM may be a result of abnormal left ventricular relaxation or decreased left ventricular compliance. Our research subjects are in the prestage of type II DM, and left ventricular compliance impairment is usually evident in the late stages of diastolic dysfunction. It is clear that at this stage, OLETF rats are free of premature atherosclerosis (histological and serological findings) and hypertension as alternative explanations, although these factors are plausible explanations for some adult rats with DM and diastolic dysfunction.
Mechanisms of Alteration in Left Ventricular
Diastolic Function in Prediabetes
The TGF-ß family has been identified in mammals, where it
modulates cell growth and differentiation as well as extracellular
matrix deposition and degradation. In this family,
TGF-ß1 is shown to play a critical role in
organ morphogenesis, development, growth regulation, cellular
differentiation, gene expression, and tissue remodeling. In rat heart,
this cytokine is involved in fibrous tissue formation and may
upregulate collagen expression during tissue repair. TGF-ßs mediate
their activity by high-affinity binding to the type II receptor with a
cytoplasmic serine-threonine kinase domain.8 9 10 On the
basis of this concept, we stained the TGF-ß1
receptor II of myocardium.
In the present study, TGF-ß1 receptor II increased significantly in the left ventricle of OLETF rats, and the ratio of collagen content/dry weight of left ventricle was significantly higher in OLETF rats than in LETO rats at 15 weeks of age. This suggested that the gene expressions of this cytokine demonstrated by the previous report18 might be induced by metabolic abnormalities (chronic postprandial hyperglycemia, hyperinsulinemia, insulin resistance) and participate in the onset of cardiac fibrosis by stimulating extracellular matrix synthesis.
On the basis of our results, the stage from 10 to 30 weeks seems to be the critical stage of DM formation, because postprandial hyperglycemia and hyperinsulinemia coexist, which reflects the existence of insulin resistance. The pathogenesis is the downregulation of the expression of insulin receptors on adipocytes and skeletal muscle cell surfaces and resultant diminished insulin binding. Although additional work is required for clarification of the influence of insulin resistance on left ventricular diastolic function, our study demonstrated that the alteration in left ventricular diastolic function was associated with the increase in cardiac collagen content at the prediabetic stage.
Limitations and Clinical Implications
The effects of anesthesia on transmitral inflow
pattern could not be completely neglected if it was possible that the 2
groups of rats responded differentially to anesthesia.
Therefore, we used only as much anesthesia as necessary to
keep the body position of the rats stable and tried to eliminate an
excessive increase in heart rate due to excitation. In addition to the
possibility of this excessive heart rate being a result of inadequate
sedation, the elimination of Doppler data for animals with heart
rates >390 bpm could have selected out a portion of the animals who
were capable of that heart rate response, ie, a greater number of
control group LETO animals were rejected because of the heart rate
response at 5 weeks and at 15 weeks. In the mildly anesthetized
condition, the number of rats with an adequate heart rate separating
early and late filling waves of transmitral inflow velocity curve was
great enough for statistical analysis.
In this study, young rats (5 weeks of age) were used. The serial data of body weight, blood pressure, serum glucose, triglyceride, cholesterol, left ventricular inflow pattern, and histopathology were obtained from 5 weeks until 47 weeks of age. This study implies an optimal timing of interventional measures. Individuals who have a genetic background of DM, even though they are young and asymptomatic, should be included in interventional procedures to prevent the development of type II DM and its complications.
Conclusions
In the prestage of type II DM, the OLETF rats showed
alteration in left ventricular diastolic
function. The alteration includes a prolongation in deceleration time
and a decrease in amplitude of peak velocity of the early
diastolic filling wave without obvious differences in blood
pressure and heart rate in OLETF rats compared with LETO rats. This
change can be tracked longitudinally with transthoracic
Doppler echocardiography and is accompanied by
serological and pathological changes of the heart. These changes may be
a result of metabolic abnormalities or a
simultaneous alteration parallel to the
metabolic abnormalities in prediabetes. The OLETF rat seems
to be a useful model to study the mechanism of alteration in cardiac
function in type II DM.
|
Received June 29, 1999; revision received August 19, 1999; accepted August 31, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Yamaji T, Fukuhara T, Kinoshita M. Increased capillary permeability to albumin in diabetic rat myocardium. Circ Res. 1993;72:947–957.
2.
Ohno M, Cheng CP, Little WC. Mechanism of altered
patterns of left ventricular filling during the development
of congestive heart failure. Circulation. 1994;89:2241–2250.
3. Ito T, Suwa M, Otake Y, Moriguchi A, Hirota Y, Kawamura K. Left ventricular Doppler filling pattern in dilated cardiomyopathy: relation to hemodynamics and left atrial function. J Am Soc Echocardiogr. 1997;10:518–525.[Medline] [Order article via Infotrieve]
4. Boyd SYN, Mego DM, Khan NA, Rubal BJ, Gilbert TM. Doppler echocardiography in cardiac transplant patients: allograft rejection and its relationship to diastolic function. J Am Soc Echocardiogr. 1997;10:526–531.[Medline] [Order article via Infotrieve]
5. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta stone. J Am Coll Cardiol. 1997;30:8–18.[Abstract]
6. Hurrell DG, Nishimura RA, Ilstrup DM, Appleton CP. Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: a simultaneous catheterization and Doppler echocardiographic study. J Am Coll Cardiol. 1997;30:459–467.[Abstract]
7. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422–1428.[Abstract]
8. Kucich U, Rosenbloom JC, Shen G, Abrams WR, Blaskovich MA, Hamilton AD, Ohkanda J, Sebti SM, Rosenbloom J. Requirement for geranylgeranyl transferase I and acyl transferase in the TGF-beta-stimulated pathway leading to elastin mRNA stabilization. Biochem Biophys Res Commun. 1998;252:111–116.[Medline] [Order article via Infotrieve]
9.
Beers MF, Solarin KO, Guttentag SH, Rosenbloom J,
Kormilli A, Gonzales LW, Ballard PL. TGF-beta 1 inhibits surfactant
component expression and epithelial cell maturation in cultured human
fetal lung. Am J Physiol. 1998;275:L950–L960.
10. Katwa LC, Sun Y, Campbell SE, Tyagi SC, Dhalla AK, Kandala JC, Weber KT. Pouch tissue and angiotensin peptide generation. J Mol Cell Cardiol. 1998;30:1401–1413.[Medline] [Order article via Infotrieve]
11.
Hamaguchi A, Kim S, Ohta K, Yagi K, Yukimura T, Miura
K, Fukuda T, Iwao H. Transforming growth
factor-ß1 expression and phenotypic
modulation in the kidney of hypertensive rats. Hypertension. 1995;26:199–207.
12. Stegemann H, Stadler K. Determination of hydroxyproline. Clin Chim Acta. 1967;18:267–273.[Medline] [Order article via Infotrieve]
13. Green H, Goldberg B. Collagen and cell protein synthesis by an established mammalian fibroblast line. Nature. 1964;24:347–349.
14.
Flesch M, Schiffer F, Zolk O, Pinto Y, Rosenkranz S,
Hirth-Dietrich C, Arnold G, Paul M, Böhm M. Contractile
systolic and diastolic dysfunction in renin-induced
hypertensive cardiomyopathy.
Hypertension. 1997;30:383–391.
15. Riggs TW, Transue D. Doppler echocardiographic evaluation of left ventricular diastolic function in adolescents with diabetes mellitus. Am J Cardiol. 1990;65:899–902.[Medline] [Order article via Infotrieve]
16. Celentano A, Vaccaro O, Tammaro P, Galderisi M, Crivaro M, Oliviero M, Imperatore G, Palmieri V, Iovino V, Riccardi G, Divitiis O. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus. Am J Cardiol. 1995;76:1173–1176.[Medline] [Order article via Infotrieve]
17. Fukuzawa Y, Watanabe Y, Inaguma D, Hotta N. Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state. J Lab Clin Med. 1996;128:568–578.[Medline] [Order article via Infotrieve]
18.
Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y,
Iwao H. Characteristics of diabetes, blood pressure, and cardiac and
renal complications in Otsuka Long-Evans Tokushima Fatty rats.
Hypertension. 1997;29:728–735.
19. Díez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res. 1997;35:202–205.[Medline] [Order article via Infotrieve]
20. Annoni G, Luvara G, Arosio B, Gagliano N, Fiordaliso F, Santambrogio D, Jeremic G, Mircoli L, Latini R, Vergani C, Masson S. Age-dependent expression of fibrosis-related genes and collagen deposition in the rat myocardium. Mech Ageing Dev. 1988;101:57–72.
21. Skorton DJ, Vandenberg B. Ultrasound tissue characterization of the diabetic heart: laboratory curiosity or clinical tool? J Am Coll Cardiol. 1992;19:1163–1164.[Medline] [Order article via Infotrieve]
22. Thompson EDW. Structural manifestations of diabetic cardiomyopathy in the rat and its reversal by insulin treatment. Am J Anat. 1988;182:270–282.[Medline] [Order article via Infotrieve]
23. Pérez JE, McGill JB, Santiago JV, Schechtman KB, Waggoner AD, Miller JG, Sobel BE. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol. 1992;19:1154–1162.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  A. W. Roberts, A. L. Clark, and K. K. Witte Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease -- do we need to screen our patients? Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 153 - 163. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Cosentino, L. Rydén, P. Francia, and L. G. Mellbin CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafian, C. W. le Roux, A. Darzi, and T. Athanasiou Effects of Bariatric Surgery on Cardiovascular Function Circulation, November 11, 2008; 118(20): 2091 - 2102. [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Lacombe, S. Viatchenko-Karpinski, D. Terentyev, A. Sridhar, S. Emani, J. D. Bonagura, D. S. Feldman, S. Gyorke, and C. A. Carnes Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1787 - R1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jesmin, S. Zaedi, N. Shimojo, M. Iemitsu, K. Masuzawa, N. Yamaguchi, C. N. Mowa, S. Maeda, Y. Hattori, and T. Miyauchi Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1030 - E1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsushima, S. Kinugawa, T. Ide, H. Matsusaka, N. Inoue, Y. Ohta, T. Yokota, K. Sunagawa, and H. Tsutsui Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2237 - H2245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jesmin, S. Zaedi, S. Maeda, C. N. Mowa, I. Sakuma, and T. Miyauchi Reversal of Elevated Cardiac Expression of TGF{beta}1 and Endothelin-1 in OLETF Diabetic Rats by Long-Acting Calcium Antagonist. Experimental Biology and Medicine, June 1, 2006; 231(6): 907 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nielson, T. Lange, and N. Hadjokas Blood Glucose and Coronary Artery Disease in Nondiabetic Patients Diabetes Care, May 1, 2006; 29(5): 998 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jesmin, Y. Hattori, S. Maeda, S. Zaedi, I. Sakuma, and T. Miyauchi Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2146 - H2154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-s. Yoon, S. Uchida, O. Masuo, M. Cejna, J.-S. Park, H.-c. Gwon, R. Kirchmair, F. Bahlman, D. Walter, C. Curry, et al. Progressive Attenuation of Myocardial Vascular Endothelial Growth Factor Expression Is a Seminal Event in Diabetic Cardiomyopathy: Restoration of Microvascular Homeostasis and Recovery of Cardiac Function in Diabetic Cardiomyopathy After Replenishment of Local Vascular Endothelial Growth Factor Circulation, April 26, 2005; 111(16): 2073 - 2085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nielson and T. Lange Blood Glucose and Heart Failure in Nondiabetic Patients Diabetes Care, March 1, 2005; 28(3): 607 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Tyagi, W. Rodriguez, A. M. Patel, A. M. Roberts, J. C. Falcone, J. C. Passmore, J. T. Fleming, and I. G. Joshua Hyperhomocysteinemic Diabetic Cardiomyopathy: Oxidative Stress, Remodeling, and Endothelial-Myocyte Uncoupling Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 1 - 10. [Abstract] [PDF]
|
|
|
|
 |
|
 J E Toblli, G Cao, G DeRosa, and P Forcada Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor {beta}1 in obese Zucker rats by perindopril Heart, January 1, 2005; 91(1): 80 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Lim, R. J. MacFadyen, and G. Y. H. Lip Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart Arch Intern Med, September 13, 2004; 164(16): 1737 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yu, K. Ohmori, Y. Chen, C. Sato, H. Kiyomoto, K. Shinomiya, H. Takeuchi, K. Mizushige, and M. Kohno Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model J. Am. Coll. Cardiol., August 18, 2004; 44(4): 904 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Y. Fang, J. B. Prins, and T. H. Marwick Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications Endocr. Rev., August 1, 2004; 25(4): 543 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. TSCHOPE, T. WALTHER, J. KONIGER, F. SPILLMANN, D. WESTERMANN, F. ESCHER, M. PAUSCHINGER, J. B. PESQUERO, M. BADER, H.-P. SCHULTHEISS, et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene FASEB J, May 1, 2004; 18(7): 828 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jesmin, I. Sakuma, Y. Hattori, and A. Kitabatake Role of Angiotensin II in Altered Expression of Molecules Responsible for Coronary Matrix Remodeling in Insulin-Resistant Diabetic Rats Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2021 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Hayashi, K Sohmiya, A Ukimura, S Endoh, T Mori, H Shimomura, M Okabe, F Terasaki, and Y Kitaura Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart Heart, October 1, 2003; 89(10): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Jugdutt and V. Menon Upregulation of Angiotensin II Type 2 Receptor and Limitation of Myocardial Stunning by Angiotensin II Type 1 Receptor Blockers during Reperfused Myocardial Infarction in the Rat Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 217 - 226. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Christoffersen, E. Bollano, M. L. S. Lindegaard, E. D. Bartels, J. P. Goetze, C. B. Andersen, and L. B. Nielsen Cardiac Lipid Accumulation Associated with Diastolic Dysfunction in Obese Mice Endocrinology, August 1, 2003; 144(8): 3483 - 3490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yu, K. Ohmori, I. Kondo, L. Yao, T. Noma, T. Tsuji, K. Mizushige, and M. Kohno Correlation of functional and structural alterations of the coronary arterioles during development of type II diabetes mellitus in rats Cardiovasc Res, November 1, 2002; 56(2): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jesmin, Y. Hattori, I. Sakuma, C. N. Mowa, and A. Kitabatake Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model Am J Physiol Heart Circ Physiol, October 1, 2002; 283 (4): H1387 - H1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Solomon, M. S. J. Sutton, G. A. Lamas, T. Plappert, J. L. Rouleau, H. Skali, L. Moye, E. Braunwald, M. A. Pfeffer, and for the Survival And Ventricular Enlargement (SAVE Ventricular Remodeling Does Not Accompany the Development of Heart Failure in Diabetic Patients After Myocardial Infarction Circulation, September 3, 2002; 106(10): 1251 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Semeniuk, A. J. Kryski, and D. L. Severson Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H976 - H982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Taegtmeyer, P. McNulty, and M. E. Young Adaptation and Maladaptation of the Heart in Diabetes: Part I: General Concepts Circulation, April 9, 2002; 105(14): 1727 - 1733. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, L. Liaudet, F. G. Soriano, J. G. Mabley, E. Szabo, and C. Szabo The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in Diabetes Diabetes, February 1, 2002; 51(2): 514 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Abe, Y. Ohga, N. Tabayashi, S. Kobayashi, S. Sakata, H. Misawa, T. Tsuji, H. Kohzuki, H. Suga, S. Taniguchi, et al. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H138 - H148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Li Yao, K. Mizushige, T. Noma, K. Murakami, K. Ohmori, and H. Matsuo Improvement of Left Ventricular Diastolic Dynamics in Prediabetic Stage of A Type II Diabetic Rat Model After Troglitazone Treatment Angiology, January 1, 2001; 52(1): 53 - 57. [Abstract] [PDF]
|
|
|
|
|
|
L YAO, K MIZUSHIGE, T NOMA, K MURAKAMI, K OHMORI, H MATSUO, and G F BAXTER Troglitazone decreases collagen accumulation in prediabetic stage of a type II diabetic rat model Heart, August 1, 2000; 84(2): 209 - 209. [Full Text]
|
|
|
|
|
|
K. Wachtell, J. N. Bella, J. Rokkedal, V. Palmieri, V. Papademetriou, B. Dahlof, T. Aalto, E. Gerdts, and R. B. Devereux Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study Circulation, March 5, 2002; 105(9): 1071 - 1076. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||